Correlation Between CCR2 Expression And Clinicopathological Characteristics And Prognosis Of Acral Malignant Melanoma

Objective:The expression level of CCR2 was detected in paraffin sections of primary lesion tissue and metastatic lymph node tissue after acral malignant melanoma by immunohistochemical method.To compare the difference of CCR2 expression in the primary lesion and metastatic lymph node tissue of metastatic acral malignant melanoma.Analyze the correlation between clinical case data,pathological characteristics and CCR2 expression in patients with acral malignant melanoma.Follow-up patients’ survival and discuss the indicators that affect the prognosis of acral malignant melanoma.Method:1.The clinical case data of 70 patients with acral malignant melanoma were collected in the Department of Orthopedics,Yunnan Cancer Hospital,from January 2015 to December 2018.Detect the expression of CCR2 in 70 cases of acral malignant melanoma lesions and the expression of CCR2 in 11 cases of metastatic lesions with immunohistochemical methods.2.Use statistical methods(χ~2 test,t test,etc.)to analyze the correlation between CCR2 and the characteristics of patients with acral malignant melanoma,such as gender,age,ulceration,tumor size,tumor invasion depth,Clark grade,and tumor clinical stage;And to compare the expression differences of CCR2 in the primary lesions and metastatic lymph node lesions of patients with metastatic acral malignant melanoma.The survival status of the collected patients with acral malignant melanoma was followed up,and the Log-Rank test was used to explore the indicators that affect the prognosis of patients with acral malignant melanoma.Results:1.CCR2 is expressed in the primary lesion tissues and metastatic lymph node tissues of patients with acral malignant melanoma,and it is mainly distributed on the cell membrane.The immunohistochemical results show that CCR2 is in 70 cases of acral malignant melanoma tissues.There are 64 cases of expression,and the positive rate of expression is 91.43%(64/70),of which 38 cases are high expression and 32 cases are low expression;CCR2 has 10 cases in 11 cases of metastatic acral malignant melanoma metastatic lymph node tissue There were 7 cases with high expression and only 4 cases with low expression.The positive rate of CCR2 expression in metastatic lymph node tissue of metastatic acral malignant melanoma was 90.91%(10/11).And the expression of CCR2 in metastatic patients’ primary lesions and metastatic lymph node tissues is not significantly different;2.The expression of CCR2 has no correlation with the age,gender,tumor area,surface ulcer,Clark grade and other characteristics of patients with acral malignant melanoma,but its expression is negatively correlated with the depth of tumor invasion and the clinical stage of the tumor;3.Seventy patients with acral malignant melanoma were followed up for 6-47 months.As of the final follow-up time(March 2021),patients with acral malignant melanoma have no symptoms in 1 or 2 years after surgery.The progression survival rates were 90%(63/70)and 52.86%(37/70),respectively.Log-Rank test results show that CCR2 expression and tumor clinical stage are independent risk factors affecting the prognosis of patients with acral malignant melanoma.Conclusions:1.CCR2 is expressed in the primary lesion tissue and metastatic lymph node tissue of patients with acral malignant melanoma,and the expression location is mainly on the cell membrane;And the expression of CCR2 in the primary lesion tissue and metastatic lymph node tissue of patients with metastatic acral malignant melanoma has no significant difference;2.The expression of CCR2 has no significant correlation with age,gender,presence or absence of ulcers,Clark staging,ALP,LDH;however,it is negatively correlated with the depth of tumor invasion and the clinical stage of the tumor;3.Log-Rank test results show that CCR2 expression and tumor clinical stage are indicators that affect the prognosis of patients with acral malignant melanoma.